NGS

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Retrieved on: 
Monday, April 8, 2024
ACT, Gene, Biotechnology, Acceleration, LOH, CDX, Risk, Patient, NGS, Biomarker, Research, MSI, DNA, Cancer, Spacecraft, AACR, MRD, Recurrence, FDA, Health, Plasma, Neoplasm, Medicine, Pharmaceutical industry

BURLINGTON, N.C., April 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to advancing cancer research and patient care on a global scale. The announcement underscores Labcorp's dedication to investing in scientific, diagnostic and laboratory innovations to support its pharmaceutical, biotechnology and clinical research partners in bringing groundbreaking therapies to market.

Key Points: 
  • The announcement underscores Labcorp's dedication to investing in scientific, diagnostic and laboratory innovations to support its pharmaceutical, biotechnology and clinical research partners in bringing groundbreaking therapies to market.
  • "Our portfolio expansion enhances our integrated services to empower our partners with the solutions and support they need to advance their development programs and make a lasting difference in patients' lives."
  • Labcorp recently announced the commercial availability of Labcorp Plasma Detect, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) MRD solution for research and investigational use.
  • Labcorp's deep scientific expertise and comprehensive solutions include specialized pre-clinical discovery, biomarker and companion diagnostics (CDx) development and post-commercialization capabilities.

Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 18, 2024
Singular, Growth, SAN, Tissue, NGS, RNA, Proteomics, Workflow, Investment, Genomics, OMIC, Network throughput, H&E, Video game

“We ended 2023 on a strong note, shipping our largest number of quarterly instruments to-date,” said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics.

Key Points: 
  • “We ended 2023 on a strong note, shipping our largest number of quarterly instruments to-date,” said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics.
  • Shipped eight G4 systems in the fourth quarter of 2023, increasing the total number of commercial systems shipped to 24 as of the end of the fourth quarter of 2023.
  • Operating expenses for the fourth quarter of 2023 totaled $24.8 million, compared to $22.5 million for the fourth quarter of 2022.
  • Operating expenses included non-cash stock-based compensation of $2.7 million for the fourth quarter of 2023 and $3.1 million for the fourth quarter of 2022.

Tempus Announces 18 Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Friday, April 5, 2024
Research, Managed Care, Pharmaceutical, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, Mutation, Survival, ESR1, Intelligence, Progression-free survival, Patient, NGS, DNA, MD, Medicine, Abstract, AACR, TRM, Clonal hematopoiesis, AIS, Liquid biopsy, Enzyme inhibitor, Annual general meeting, Medical imaging

Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California.
  • Tempus researchers will demonstrate how the company’s AI-enabled precision medicine platform collects and analyzes high-quality, multimodal datasets to advance cancer research.
  • “We look forward to presenting 18 abstracts at AACR this year, demonstrating the breadth and depth of our research both at Tempus and with our biopharma collaborators,” said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus.
  • These preliminary findings suggest that xM used for TRM can identify patients with ESR1m and poor response on AI who may benefit from switching therapy.

United States Clinical Oncology Next Generation Sequencing Market Research Report 2023-2028: Data Analysis and Interpretation Tools to Streamline Processes and Growth in Genomic Medicine - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Genetics, Health, Oncology, Lifestyle, Theft, Genomics, Growth, Prevalence, Disease, Data analysis, Incidence, Risk, Patient, NGS, Health care, Cancer, Risk assessment, Laboratory, Quality of life, Medicine, Confidentiality, Identity theft, HIPAA, Interpretation, Treatment, Investment, Privacy, Medical imaging

United States Clinical Oncology Next Generation Sequencing Market is anticipated to project robust growth in the forecast period.

Key Points: 
  • United States Clinical Oncology Next Generation Sequencing Market is anticipated to project robust growth in the forecast period.
  • The United States Clinical Oncology Next Generation Sequencing (NGS) market is a dynamic and rapidly evolving sector within the broader healthcare and life sciences industry.
  • The United States is a global leader in clinical oncology NGS, with numerous academic institutions, research centers, and biotechnology companies actively engaged in cutting-edge research and development.
  • Additionally, data analysis tools that adhere to standardized formats promote collaboration, knowledge exchange, and innovation in clinical oncology.

Drug Discovery and Early Development Outsourcing Services Industry Analysis - M&As, Partnerships and the Shift Toward an End-to-end CRDMO Model will Boost Sector Expansion - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, ChromeOS, ROI, Growth, Neurology, PROTAC, Drug discovery, Partnership, COVID-19, HTS, NGS, RNA, Artificial intelligence, Overalls, Drug development, Machine learning, Fine chemical

The "Growth Opportunities in Drug Discovery and Early Development Outsourcing Services" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities in Drug Discovery and Early Development Outsourcing Services" report has been added to ResearchAndMarkets.com's offering.
  • Overall R&D expenditure totals about $276.81 billion, with a slow 2.5% growth between 2023 to 2024.
  • This activity is improving the partnership landscape across the global drug discovery and preclinical development industry.
  • Last, the larger CROs have developed separate lab testing divisions that allow them to focus on specific drug discovery and preclinical development testing services.

Antibody Solutions Secures Grant for Challenging Diagnostic Initiative

Retrieved on: 
Thursday, April 4, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Infectious Diseases, Genetics, LDH, Infection, Bill, RDT, Risk, Public, NGS, Antibody Solutions, Doctor of Philosophy, LMIC, Biology, Malaria, Antibody, Melinda French Gates, Vaccine

Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that it received a 15-month grant for nearly $1.2 million from the Bill & Melinda Gates Foundation to develop reagents for highly-specified rapid diagnostic tests (RDT) to detect malaria.

Key Points: 
  • Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that it received a 15-month grant for nearly $1.2 million from the Bill & Melinda Gates Foundation to develop reagents for highly-specified rapid diagnostic tests (RDT) to detect malaria.
  • The end result is that those RDTs are unable to differentiate between different strains of malaria,” explained John Kenney, PhD, co-founder and president of Antibody Solutions.
  • ”
    Antibody Solutions has already begun work to identify these new antibody reagents by harnessing Cellestive, its antibody discovery platform, that includes multiple discovery pathways such as hybridoma library, primary B-cell screening, and guided next-generation sequencing (NGS).
  • The grant from the foundation will also allow Antibody Solutions to work with industry experts in both public health and the development and deployment of healthcare solutions in low- and middle-income (LMIC) settings, ensuring that these reagents will be widely available.

Agilent at AACR 2024: Empowering Breakthroughs in Cancer Research and Diagnostics

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Health, Health Technology, Genetics, Other Science, Research, Science, Genomics, IHC, Methylation, Partnership, Laser, TMB, NGS, MSI, DNA, Biomarker, Cancer, Hydrofluoroolefin, Biology, Medicine, Imperial College London, AACR, Microsatellite instability, Neoplasm, Therapy, Agilent Technologies, Liquid biopsy, Machine learning, RNA-Seq, University of Oxford, CMO, Medical imaging

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences and diagnostics, announced today its participation in the American Association for Cancer Research Annual Meeting (AACR) .

Key Points: 
  • Agilent Technologies Inc. (NYSE: A), a global leader in life sciences and diagnostics, announced today its participation in the American Association for Cancer Research Annual Meeting (AACR) .
  • Agilent Avida - Agilent Avida’s new cutting-edge target enrichment solutions enable simultaneous DNA and methylation profiling from a single sample.
  • Agilent SureSelect Cancer Custom panels - Agilent SureSelect Cancer Custom panels offer the ability to add new and emerging biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI), to custom tumor genomic profiling assays.
  • AACR attendees can also explore multiple Agilent research posters and over 50 additional customer posters highlighting Agilent instruments and solutions.

Takara Bio transforms single-cell landscape with new large-scale NGS profiling system for oncology biomarker discovery

Retrieved on: 
Tuesday, April 2, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Single-cell analysis, Cell, NGS, Biomarker, RNA, ABRF, Messenger, Head, AACR, Chemistry, Neoplasm, Booth, RNA-Seq, WGA, SNV, Annual general meeting, CNV, Vaccine

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Shasta™ Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.

Key Points: 
  • Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Shasta™ Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.
  • Existing whole-genome amplification (WGA) technologies currently process 96–384 single cells per plate; the Shasta system increases WGA throughput to 1,500 cells per run.
  • In March, Takara Bio USA delivered instruments and NGS kits to early-access users, who have started producing results with the system.
  • We have two other projects in the lab where we want to do a full set of profiling of our entire model system.

Global and Regional MRD Testing Market Analysis Report 2024: Revolutionizing Cancer Patient Management, Rising Consumer Awareness Spurs Demand for MRD Testing - Forecast to 2033 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2024
Surgery, Medical Devices, Hospitals, Genetics, Health Technology, Biotechnology, Radiology, Health, Oncology, Hospital, PCR, Flow cytometry, Chronic leukemia, Growth, Bone marrow, Incidence, Integration, Patient, NGS, IDT, Research, Health care, Multiple myeloma, Acquisition, Cancer, Medicare, Medicine, Karyotype, MRD, Haematopoietic system, Region, GRAIL, Throttle position sensor, Lymphoma, Polymerase chain reaction, Medical imaging

The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The MRD testing market is driven by several factors, including the expansion in medicare coverage for MRD testing and the administration of solid tumor diagnosis.
  • In recent years, as consumer awareness has grown, there has been an increasing demand for MRD testing.
  • The global MRD testing market is a rapidly growing segment in the healthcare industry, driven by the increasing demand for accurate and sensitive methods to monitor and manage cancer patients.

NGS Is First to Market with Revolutionary 3M Glazing Security Product – S2400

Retrieved on: 
Wednesday, March 27, 2024
Commercial Building & Real Estate, Technology, Construction & Property, Interior Design, Building Systems, Other Energy, Security, Other Technology, Energy, Hardware, Other Construction & Property, Multimedia, NGS, Interest, Safety

NGS worked directly with 3M to field-test and provide feedback to help bring this product to market.

Key Points: 
  • NGS worked directly with 3M to field-test and provide feedback to help bring this product to market.
  • View the full release here: https://www.businesswire.com/news/home/20240327037471/en/
    “We’re so excited to be the first dealer-installer to bring 3M S2400 to market,” states James Beale, CEO.
  • “This innovative product is a game-changer for glazing security and building perimeter security.
  • NGS is excited to bring 3M S2400 to clients who value the safety and security of their buildings.